IDNA — IDNA Genomics Public Share Price
0.000.00%
Last trade - 00:00- €27.65m
- €28.80m
- €0.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 54.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -608.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.78 | 1.08 | 0.49 | 0.48 | 0.49 | n/a | n/a | -10.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
iDNA Genomics Public Ltd is a Cyprus-based company active in the precision medicine and genetic analysis sector. The Company provides genetic analysis services in areas including pharmacogenetics, preventive medicine, nutrition, and sports genomics. It offers DNA analysis services designed to provide individuals with information regarding their genetic characteristics through personalized reports. The Company operates laboratory facilities and utilizes proprietary bioinformatics and data-processing platforms to analyze genetic and biological data. Its services incorporate molecular analysis techniques and bioinformatics tools to support the generation and interpretation of genetic analysis results. The Company's analyses are based on published scientific literature and data from international scientific databases.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- November 16th, 2020
- Public Since
- December 17th, 2021
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Cyprus Stock Exchange
- Shares in Issue
- 2,764,500
- Address
- Odos Chatzidaki 7, 3Os Orofos, Trypiotis, NICOSIA, 1066
- Web
- https://idnagenomics.com/
- Phone
- +357 22422240
- Auditors
- ADM Audit Trust Limited
Upcoming Events for IDNA
FAQ
What is the IDNA Genomics Public share price?
As of Today at 02:15 UTC, shares in IDNA Genomics Public are trading at €10.00. This share price information is delayed by 15 minutes.
How has the IDNA Genomics Public share price performed this year?
Shares in IDNA Genomics Public last closed at €10.00 and the price had moved by -65.99% over the past 365 days. In terms of relative price strength the IDNA Genomics Public share price has underperformed the FTSE Global All Cap Index by -69.96% over the past year.
What are the analyst and broker recommendations for IDNA Genomics Public?
There is no consensus recommendation for this security.
Find out moreWhat is the IDNA Genomics Public dividend yield?
IDNA Genomics Public does not currently pay a dividend.
Does IDNA Genomics Public pay a dividend?
IDNA Genomics Public does not currently pay a dividend.
When does IDNA Genomics Public next pay dividends?
IDNA Genomics Public does not currently pay a dividend.
How do I buy IDNA Genomics Public shares?
To buy shares in IDNA Genomics Public you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IDNA Genomics Public?
As of the previous close price of €10.00, shares in IDNA Genomics Public had a market capitalisation of €27.65m.
Where are IDNA Genomics Public shares listed?
Here are the trading details for IDNA Genomics Public:
- Country of listing: Cyprus
- Exchange: CYS
- Ticker Symbol: IDNA
What kind of share is IDNA Genomics Public?
Based on an overall assessment of its quality, value and momentum IDNA Genomics Public is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IDNA Genomics Public share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the IDNA Genomics Public share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IDNA Genomics Public. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -59.17%.
As of the last closing price of €10.00, shares in IDNA Genomics Public were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IDNA Genomics Public PE Ratio?
The IDNA Genomics Public PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €10.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IDNA Genomics Public?
We do not have data on IDNA Genomics Public's directors